[Reduction of cholesterol and myocardial infarction. Big differences between different groups when it comes to the therapeutic effect]

[Article in Swedish]

Affiliations

Review

[Article in Swedish]

J Håkansson. Lakartidningen. 1997.

. 1997 Dec 3;94(49):4619, 4622-3.

No abstract available

Similar articles

[Critical evaluation of indications for lipid reduction. Cholesterol value updated--risk counts (interview by Dr. Kirsten Westphal)].
Motz W. Motz W. MMW Fortschr Med. 2003 Oct 9;145(41):48. MMW Fortschr Med. 2003. PMID: 14655487 German. No abstract available.
[Victory in primary prevention--or? Can we afford to translate results from the West-of-Scotland Study into general practice?].
Klose G. Klose G. Fortschr Med. 1996 Jun 20;114(17):231-2. Fortschr Med. 1996. PMID: 8767302 Clinical Trial. German. No abstract available.
Cost-effectiveness of pravastatin therapy for survivors of myocardial infarction with average cholesterol levels.
Tsevat J, Kuntz KM, Orav EJ, Weinstein MC, Sacks FM, Goldman L. Tsevat J, et al. Am Heart J. 2001 May;141(5):727-34. doi: 10.1067/mhj.2001.114805. Am Heart J. 2001. PMID: 11320359 Clinical Trial.
Perspectives in cholesterol-lowering therapy: the role of ezetimibe, a new selective inhibitor of intestinal cholesterol absorption.
Bruckert E, Giral P, Tellier P. Bruckert E, et al. Circulation. 2003 Jul 1;107(25):3124-8. doi: 10.1161/01.CIR.0000072345.98581.24. Circulation. 2003. PMID: 12835406 Review. No abstract available.
[How I treat and manage cholesterol after myocardial infarction].
Capron L. Capron L. Journ Annu Diabetol Hotel Dieu. 1996:199-209. Journ Annu Diabetol Hotel Dieu. 1996. PMID: 8965423 Review. French. No abstract available.